The connection is probably that ApoE4 carriers clear out amyloid beta deposits less efficiently than ApoE3/2 carriers (see e.g. [1] among many other sources), whereas microbial infection can induce amyloid deposits to…
Amyloid-targeting drugs have not failed. There are currently three — aducanumab (phase 2 trial successful, one of two phase 3 trials successful), donanemab (successful phase 2 trial), and lecanemab (promising phase 2…
The connection is probably that ApoE4 carriers clear out amyloid beta deposits less efficiently than ApoE3/2 carriers (see e.g. [1] among many other sources), whereas microbial infection can induce amyloid deposits to…
Amyloid-targeting drugs have not failed. There are currently three — aducanumab (phase 2 trial successful, one of two phase 3 trials successful), donanemab (successful phase 2 trial), and lecanemab (promising phase 2…